Page 1
Angiogenesis in Cancer New opportunities for therapeutic intervention
Enrique Zudaire
Page 2
Vasculogenesis vs Angiogenesis
Page 3
Angiogenesis: Physiological and Pathological
Page 8
Normal blood vessels are less permeable and have
more pericytes than do tumor blood vessels l
Page 9
McDonald & Choyke Nat Med 2003 St Croix Cancer Cell 2007 11:539:54
Normal Blood Vessels versus Tumor blood vessels.
Page 10
The angiogenic switch and
antiangiogenic therapy
Page 11
Antiangiogenic therapy in preclinical models. When Dr. Judah Folkman is asked whether he
can cure cancer, he invariably replies, “Yes, in
mice.”
Page 14
“Diversity” in angiogenesis
research
Page 15
Anti-VEGF in preclinical models
of cancer and the clinic
Page 16
Successful phase III clinical
trails
Page 17
Unsuccessful phase III clinical
trials
Page 18
Do VEGF-pathway inhibitors
augment growth, invasion or
metastatic potential
Page 19
Bevacizumab clinical trial
Page 20
Hypertensive and prothrombotic
activities of angogenesis
inhibitors
Page 21
Bevacizumab, Fatal Adverse
Effects
Page 22
The challenges, the needs
Page 23
Novel angiogenesis targets
Page 24
Tumor endothelial markers
Page 26
Genetic and pharmacological
effects on TEM8